Evidence map›Paper›PMID 35603628›Full record

ReviewFuture oncology (London, England)2022

A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC).

Farshid Dayyani, Brian R Smith, Ninh T Nguyen, Shaun Daly, Marcelo W Hinojosa, Steven N Seyedin, Jeffrey Kuo, Jason B Samarasena, John G Lee, Thomas H Taylor and 2 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Farshid DayyaniDepartment of Medicine, University of California Irvine, Orange, CA 92868, USA.ORCID 0000-0002-4970-5189
Brian R SmithDepartment of Surgery, University of California Irvine, Orange, CA 92868, USA.
Ninh T NguyenDepartment of Surgery, University of California Irvine, Orange, CA 92868, USA.
Shaun DalyDepartment of Surgery, University of California Irvine, Orange, CA 92868, USA.
Marcelo W HinojosaDepartment of Surgery, University of California Irvine, Orange, CA 92868, USA.
Steven N SeyedinDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
Jeffrey KuoDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
Jason B SamarasenaDepartment of Medicine, University of California Irvine, Orange, CA 92868, USA.
John G LeeDepartment of Medicine, University of California Irvine, Orange, CA 92868, USA.
Thomas H TaylorDepartment of Epidemiology, University of California Irvine, Irvine, CA 92617, USA.
May T ChoDepartment of Medicine, University of California Irvine, Orange, CA 92868, USA.
Maheswari SenthilDepartment of Surgery, University of California Irvine, Orange, CA 92868, USA.
University of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Chao Family Comprehensive Cancer Center Pilot AwardNatera Inc.NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

Current guidelines recommend neoadjuvant (NAC) and/or adjuvant chemotherapy for locally advanced gastric cancers (LAGCs). However, the choice and duration of NAC regimen is standardized, rather than personalized to biologic response, despite the availability of several different classes of agents for the treatment of gastric cancer (GC). The current trial will use a tumor-informed ctDNA assay (Signatera™) and monitor response to NAC. Based on ctDNA kinetics, the treatment regimen is modified. This is a prospective single center, single-arm, open-label study in clinical stage IB-III GC. ctDNA is measured at baseline and repeated every 8 weeks. Imaging is performed at the same intervals. The primary end point is the feasibility of this approach, defined as percentage of patients completing gastrectomy.

Indexed as

Neoadjuvant TherapyStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantClinical Trials, Phase I as TopicFeasibility StudiesGastrectomyHumansNeoplasm StagingProspective StudiesctDNAgastrectomygastric cancerneoadjuvant chemotherapy

Identifiers

PMID35603628
PMCPMC9437768
OpenAlexW4281298302

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.